Found 7 matching trials
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies PHASE2 There is no curative therapy once acute leukemia patients relapse after tra...
Show More Location
University of California
Learn More & Join Trial
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) PHASE1 Primary Objectives:
This a pilot project to determine the feasibility of t...
Show More Location
Department of Hematology-Oncology, National University Hospital
Learn More & Join Trial
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS PHASE1 The study examines the application of expanded natural killer cells (NK cel...
Show More Location
University Hospital Basel
Learn More & Join Trial
Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia PHASE2 Usually Chronic lymphocytic leukemia (CLL) is a disease of the elderly pati...
Show More Location
CHU Clermont-Ferrand
Learn More & Join Trial
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT NA Donor lymphocyte infusion (DLI) based on minimal residual disease (MRD) has...
Show More Location
Multiple Locations
Learn More & Join Trial
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT PHASE2 Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective t...
Show More Location
Department of Hematology,Nanfang Hospital, Southern Medical University
Learn More & Join Trial
Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion PHASE2 Allogeneic stem cell transplantation, the only known curative modality for ...
Show More Location
Rambam Health Care Campus
Learn More & Join Trial